8 completed, 5 recruiting, 1 active not recruiting, 1 withdrawn. 6 Phase 3, 5 Phase 4, 4 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 3, Recruiting 3 |
| Phase 4 | 5 | Completed 2, Active not recruiting 1, Recruiting 1, Withdrawn 1 |
| Not applicable | 4 | Completed 3, Recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Colorado Prevention Center: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease Algorithm- and multi-professional team-supported lipid management, Guideline-directed lipid management by usual care provider - Hyperlipidemia | Not applicable | Recruiting | Colorado Prevention Center | 100 | 2025-12-10 | 2026-01-23 |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo) - Percutaneous Coronary Intervention, Peripheral Endovascular Intervention | Phase 4 | Recruiting | Duke University | 6000 | 2025-07-23 | 2026-10-23 |
| A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists Finerenone, Placebo - Heart Failure | Phase 3 | Recruiting | Colorado Prevention Center | 2600 | 2024-08-20 | 2026-07-10 |
| A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) Finerenone, Empagliflozin - Heart Failure | Phase 3 | Recruiting | Colorado Prevention Center | 1500 | 2024-07-09 | 2026-09-10 |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients Finerenone, Placebo - Heart Failure, Acute Heart Failure | Phase 3 | Recruiting | Colorado Prevention Center | 5200 | 2024-01-17 | 2026-09-10 |
| EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction Evolocumab, Routine Lipid Management - Cardiovascular Disease, Myocardial Infarction | Phase 4 | Active not recruiting | Amgen | 6019 | 2022-10-26 | 2025-10-06 |
| Virta Intervention in CommuniTies in cOloRado (VICTOR-Pilot) Virta Health - Diabetes Mellitus, Type 2 | Not applicable | Completed | Colorado Prevention Center | 51 | 2021-03-02 | 2025-03-11 |
| Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19 rNAPc2, Heparin - Covid19 | Phase 2 / Phase 3 | Completed | ARCA Biopharma, Inc. | 160 | 2020-12-10 | 2023-02-21 |
| Implementation of Vascular Care Team to Improve Medical Management of PAD Patients Intervention A - Vascular Care + site 6MWT administration, Intervention B - Standard Care + site 6MWT administration, Intervention A - Vascular Care + CPC EQuIP 6MWT administration - Peripheral Artery Disease | Not applicable | Completed | Colorado Prevention Center | 166 | 2020-07-07 | 2024-02-08 |
| Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities Rivaroxaban (Xarelto, BAY59-7939), Rivaroxaban-Placebo - Peripheral Artery Disease | Phase 3 | Completed | Bayer | 6564 | 2015-08-18 | 2020-12-08 |
| An Observational Study of the Functional Capacity of Heart Failure 6 Minute Walk Test - Acute Heart Failure | Not applicable | Completed | Bristol-Myers Squibb | 51 | 2014-11-01 | 2016-07-01 |
| Role of Mobile Technology to Improve Diabetes Care in Adults With Type 1 Diabetes: the REMOTE-T1D Study, a Pilot Study iBGStar meter - Type 1 Diabetes | Phase 4 | Completed | University of Colorado, Denver | 100 | 2012-12-01 | 2014-05-21 |
| Evaluation of Cilostazol in Combination With L-Carnitine Levocarnitine tartrate, cilostazol - Peripheral Vascular Disease, Intermittent Claudication | Phase 4 | Completed | Colorado Prevention Center | 164 | 2008-09-01 | 2019-11-29 |
| Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease Ranolazine, Placebo - Peripheral Arterial Disease, Angina | Phase 4 | Withdrawn | Colorado Prevention Center | 2008-05-01 | 2014-08-15 | |
| Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication) Propionyl-L-Carnitine, PLC - Peripheral Vascular Diseases, Intermittent Claudication | Phase 3 | Completed | Sigma-Tau Research, Inc. | 69 | 2006-04-01 | 2011-08-25 |
Peripheral Arterial Disease (5) · Heart Failure (4) · Cardiovascular Diseases (2) · Coronary Artery Disease (2) · Intermittent Claudication (2) · Peripheral Vascular Diseases (2) · Angina Pectoris (1) · Atherosclerosis (1) · COVID-19 (1) · Carotid Artery Diseases (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Hypercholesterolemia (1) · Hyperlipidemias (1)
finerenone (3) · ALN-PCS (1) · Algorithms (1) · Carnitine (1) · Cilostazol (1) · Heparin (1) · Ranolazine (1) · Rivaroxaban (1) · Saline Solution (1) · anti-coagulant protein C2, Ancylostoma caninum (1) · empagliflozin (1) · evolocumab (1)
United States (15) · Brazil (6) · Argentina (4) · Canada (4) · Spain (4) · United Kingdom (4) · Czechia (3) · Hungary (3) · Italy (3) · Poland (3) · Sri Lanka (3) · Bulgaria (2) · China (2) · Croatia (2) · Germany (2)
Marc Bonaca, MD (2) · Bruce Cutler (1) · Cecilia Low Wang, MD (1) · Connie Hess, MD (1) · Edgar Carell (1) · Karl Illig (1) · Kenneth Morris (1) · Layne Yonehiro (1) · Manesh Patel, MD (1) · Marc Bonaca, MD, MPH (1) · Mark R Nehler, MD (1) · Michael Koren (1) · Neil Goldenberg, MD, PhD (1)
PMID 20861750, PMID 22615190, PMID 28555339, PMID 29754671, PMID 32222135, PMID 33138628, PMID 33186199, PMID 34010631, PMID 34380322, PMID 34711335, PMID 35467452, PMID 35699170, PMID 36470531, PMID 37381988, PMID 38377256, PMID 38493348, PMID 41128134, PMID 41757414
2014 (1)